CardioDx’s Corus CAD blood-based gene expression test has demonstrated superior performance in a trial.
Corus CAD, a sex-specific blood-based test, can help clinicians and cardiologists evaluate whether a non-diabetic patient’s symptoms are due to obstructive coronary artery disease.
Go deeper with GlobalData
The prospective, blinded, multicentre study is intended to validate the CardioDx blood-based gene expression test for eliminating obstructive coronary artery disease and to compare the diagnostic performance of Corus CAD to myocardial perfusion imaging.
COMPASS enrolled 537 stable patients with symptoms suggestive of coronary artery disease, and found 89% sensitivity and 96% negative predictive value with Corus CAD compared to 27% and 88% with myocardial perfusion imaging.
University of California-Irvine School of Medicine Nuclear cardiology education director Gregory Thomas said that the use of new gene expression test, followed by myocardial perfusion imaging will optimise diagnostic performance and the use of healthcare resources.
"COMPASS builds on previous results of the PREDICT trial. In this real-world patient population, the Corus CAD test demonstrates very high sensitivity and negative predictive value, enabling clinicians to rule out patients who do not have obstructive coronary artery disease with high accuracy," Thomas said.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
